Why Europe must continue investing in biotech innovation
- 3 days ago
- 2 min read
Europe is home to some of the world's leading life sciences research institutions. Every year, scientists across the continent make discoveries with the potential to transform healthcare, agriculture and environmental sustainability.
Turning scientific discoveries into therapies that benefit patients, however, requires much more than excellent research. It depends on long-term investment, technology transfer, entrepreneurship and strong collaboration between academia, industry and investors.
A recent feature by Labiotech.eu explores how VIB has built one of Europe's leading biotechnology ecosystems over the past 30 years. Obulytix is proud to contribute to this ecosystem by developing innovative therapies to combat antimicrobial resistance.
Obulytix: developing Precision Lysin Therapeutics against antimicrobial resistance
Obulytix was founded as a spin-off from Ghent University and KU Leuven with one clear mission: developing the next generation of targeted anti-infective therapies.
Our research focuses on Precision Lysin Therapeutics (PLTs), a novel class of engineered biologics designed to selectively eliminate multidrug-resistant Gram-negative bacteria.
Unlike conventional antibiotics, PLTs combine the natural bacteria-killing activity of lysins with advanced protein engineering to create molecules that remain active under human physiological conditions. Their precision enables them to target harmful bacteria while reducing the likelihood of resistance development.
Our first therapeutic candidates are being developed for severe bloodstream and lung infections affecting vulnerable hospital patients, including intensive care and immunocompromised patients.
Why antimicrobial resistance is one of healthcare's greatest challenges
Antimicrobial resistance (AMR) is recognised as one of the greatest global health threats of our time.
As bacteria become increasingly resistant to existing antibiotics, infections become more difficult to treat. This leads to longer hospital stays, increased healthcare costs and higher mortality rates worldwide.
Developing innovative alternatives to traditional antibiotics has therefore become an urgent priority. Bringing a new therapy from laboratory research to clinical application requires years of scientific research, significant investment and close collaboration between researchers, clinicians, investors and biotechnology companies.
Why biotechnology ecosystems drive innovation
Scientific breakthroughs rarely happen in isolation.
Successful biotechnology companies grow within ecosystems where universities, research institutes, entrepreneurs, investors and technology transfer organisations work together to accelerate innovation.
For more than three decades, VIB has demonstrated how this collaborative model helps translate fundamental scientific discoveries into companies addressing major healthcare and agricultural challenges.
As one of the companies within this ecosystem, Obulytix benefits from an environment where scientific excellence, entrepreneurship and strategic partnerships reinforce one another.
Investing in European biotechnology means investing in future healthcare
Europe continues to generate exceptional scientific discoveries. The next challenge is ensuring these innovations are also financed, developed and commercialised within Europe.
Continued investment in biotechnology strengthens Europe's competitiveness, supports economic growth and accelerates the development of innovative therapies for patients worldwide.
At Obulytix, we are proud to contribute to this mission by advancing Precision Lysin Therapeutics (PLTs) for the treatment of multidrug-resistant bacterial infections and by working alongside partners who believe today's scientific discoveries can become tomorrow's healthcare solutions.
This article was inspired by a recent feature published by Labiotech.eu, which highlighted VIB's role in building one of Europe's leading biotechnology ecosystems and recognized Obulytix as one of the ecosystem's contributing innovators.
